aTyr Investors Offered Chance to Lead Securities Fraud Lawsuit

National shareholder‑rights firm The Schall Law Firm is inviting investors who purchased shares of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16 and September 12, 2025 to step forward and possibly serve as lead plaintiff in a proposed securities class action. The lawsuit alleges aTyr and certain executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b‑5 by issuing materially false and misleading statements regarding the design and execution of its Phase 3 trial of efzofitimod, particularly the company’s claim that the drug would allow patients to fully taper steroid use — a claim that investors say was hidden from the market until the truth emerged, causing investor losses. The Schall Law Firm reminds affected shareholders they have until December 8, 2025 to contact the firm and consider their options. #aTyrPharma #SecuritiesFraud #ShareholderRights #ClassAction #SlimScan #GrowthStocks #CANSLIM